JP2016505617A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016505617A5 JP2016505617A5 JP2015551659A JP2015551659A JP2016505617A5 JP 2016505617 A5 JP2016505617 A5 JP 2016505617A5 JP 2015551659 A JP2015551659 A JP 2015551659A JP 2015551659 A JP2015551659 A JP 2015551659A JP 2016505617 A5 JP2016505617 A5 JP 2016505617A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- compound
- subject
- itpr2
- molecule
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 claims 25
- 150000001875 compounds Chemical class 0.000 claims 10
- 102000007640 Inositol 1,4,5-Trisphosphate Receptors Human genes 0.000 claims 8
- 108010032354 Inositol 1,4,5-Trisphosphate Receptors Proteins 0.000 claims 8
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 6
- 208000008454 Hyperhidrosis Diseases 0.000 claims 6
- 108020004459 Small interfering RNA Proteins 0.000 claims 5
- 108020004999 messenger RNA Proteins 0.000 claims 5
- 230000035900 sweating Effects 0.000 claims 5
- 238000000034 method Methods 0.000 claims 4
- 108020004707 nucleic acids Proteins 0.000 claims 4
- 102000039446 nucleic acids Human genes 0.000 claims 4
- 150000007523 nucleic acids Chemical class 0.000 claims 4
- 230000037317 transdermal delivery Effects 0.000 claims 3
- 239000003937 drug carrier Substances 0.000 claims 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims 2
- 230000008685 targeting Effects 0.000 claims 2
- 102000040650 (ribonucleotides)n+m Human genes 0.000 claims 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims 1
- 108091006146 Channels Proteins 0.000 claims 1
- 108091026890 Coding region Proteins 0.000 claims 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical group OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 claims 1
- 239000000443 aerosol Substances 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229910052791 calcium Inorganic materials 0.000 claims 1
- 239000011575 calcium Substances 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 125000002091 cationic group Chemical group 0.000 claims 1
- 238000007385 chemical modification Methods 0.000 claims 1
- 239000006071 cream Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000037315 hyperhidrosis Effects 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 238000002347 injection Methods 0.000 claims 1
- 239000007924 injection Substances 0.000 claims 1
- 150000002632 lipids Chemical class 0.000 claims 1
- 239000002502 liposome Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000002674 ointment Substances 0.000 claims 1
- 229920000962 poly(amidoamine) Polymers 0.000 claims 1
- 108090000765 processed proteins & peptides Proteins 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
- 230000003248 secreting effect Effects 0.000 claims 1
- -1 stick Substances 0.000 claims 1
- 210000004243 sweat Anatomy 0.000 claims 1
- 210000000106 sweat gland Anatomy 0.000 claims 1
- 238000007910 systemic administration Methods 0.000 claims 1
- 238000011200 topical administration Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361748592P | 2013-01-03 | 2013-01-03 | |
| US61/748,592 | 2013-01-03 | ||
| PCT/SE2013/051508 WO2014107124A1 (en) | 2013-01-03 | 2013-12-13 | Treatment of hyperhidrosis |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016505617A JP2016505617A (ja) | 2016-02-25 |
| JP2016505617A5 true JP2016505617A5 (enExample) | 2016-09-15 |
| JP6242402B2 JP6242402B2 (ja) | 2017-12-06 |
Family
ID=51062371
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551659A Active JP6242402B2 (ja) | 2013-01-03 | 2013-12-13 | 多汗症の治療 |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US9809820B2 (enExample) |
| EP (1) | EP2958572B1 (enExample) |
| JP (1) | JP6242402B2 (enExample) |
| CN (1) | CN105025903B (enExample) |
| CA (1) | CA2896939C (enExample) |
| WO (1) | WO2014107124A1 (enExample) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9809820B2 (en) * | 2013-01-03 | 2017-11-07 | Hidros Therapeutics International Ab | Treatment of hyperhidrosis |
| BR112017018029B1 (pt) | 2015-03-20 | 2021-06-15 | Unilever Ip Holdings B.V. | Molécula de sirna, método para a redução da perspiração, composição antiperspirante e uso de uma composição antiperspirante |
| CN110643598A (zh) * | 2018-06-26 | 2020-01-03 | 煌鼎科技有限公司 | 促进皮肤凹疤愈合及毛孔收缩的酵母dna原料制法 |
| WO2024104663A1 (en) | 2022-11-16 | 2024-05-23 | Unilever Ip Holdings B.V. | Method of reducing malodour |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0019055D0 (en) * | 2000-08-03 | 2000-09-27 | Unilever Plc | Antiperspirant and deodorant products and methods for their use |
| US20040138187A1 (en) | 2002-08-28 | 2004-07-15 | Reading Christopher L. | Therapeutic treatment methods |
| EP2141234B1 (en) * | 2003-03-21 | 2016-04-27 | Roche Innovation Center Copenhagen A/S | Short Interfering RNA (siRNA) Analogues |
| AU2005248147A1 (en) * | 2004-05-11 | 2005-12-08 | Alphagen Co., Ltd. | Polynucleotides for causing RNA interference and method for inhibiting gene expression using the same |
| WO2007046102A2 (en) * | 2005-10-19 | 2007-04-26 | Menni Menashe Zinger | Methods for the treatment of hyperhidrosis |
| MX2010004262A (es) | 2007-10-18 | 2010-05-14 | Stiefel Res Australia Pty Ltd | Formulaciones topicas de glicopirrolato. |
| CN102300578A (zh) | 2008-12-01 | 2011-12-28 | 延寿有限责任公司 | 用于改变健康、安康和寿命的方法和组合物 |
| EP2464365A2 (en) | 2009-08-14 | 2012-06-20 | Allergan, Inc. | Methods of treating cancer using tachykinin retargeted endopeptidases |
| WO2012112422A1 (en) * | 2011-02-14 | 2012-08-23 | Allergan, Inc. | Inhibiting aberrant blood vessel formation using growth factor retargeted endopeptidases |
| US9809820B2 (en) * | 2013-01-03 | 2017-11-07 | Hidros Therapeutics International Ab | Treatment of hyperhidrosis |
-
2013
- 2013-12-13 US US14/759,153 patent/US9809820B2/en active Active
- 2013-12-13 CA CA2896939A patent/CA2896939C/en active Active
- 2013-12-13 CN CN201380069414.3A patent/CN105025903B/zh active Active
- 2013-12-13 WO PCT/SE2013/051508 patent/WO2014107124A1/en not_active Ceased
- 2013-12-13 EP EP13870321.0A patent/EP2958572B1/en active Active
- 2013-12-13 JP JP2015551659A patent/JP6242402B2/ja active Active
-
2017
- 2017-09-19 US US15/709,249 patent/US10633661B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019210578B2 (en) | C/EBP alpha saRNA compositions and methods of use | |
| Lee et al. | A Glu-urea-Lys ligand-conjugated lipid nanoparticle/siRNA system inhibits androgen receptor expression in vivo | |
| US11965163B2 (en) | HNF4a saRNA compositions and methods of use | |
| US10081598B2 (en) | Cationic lipid | |
| TR201908314T4 (tr) | Glutatyon bazlı ilaç dağıtım sistemi. | |
| WO2012170957A8 (en) | Retinoid-liposomes for enhancing modulation of hsp47 expression | |
| RU2013148024A (ru) | Композиции и способы ингибирования экспрессии гена tmprss6 | |
| JP2011516094A5 (enExample) | ||
| NZ718817A (en) | Lipid formulations for delivery of messenger rna | |
| JP2018504896A (ja) | 分子の細胞内送達のためのペプチドおよびナノ粒子 | |
| JP2014518612A5 (enExample) | ||
| JP2016505617A5 (enExample) | ||
| CN108779463A (zh) | 使用靶向IL4Rα、TRPA1或F2RL1的RNA复合物治疗特应性皮炎和哮喘 | |
| US20240016940A1 (en) | Long-acting and long-circulating delivery vehicles | |
| JP6242402B2 (ja) | 多汗症の治療 | |
| JP2013542196A5 (enExample) | ||
| US11149271B2 (en) | Method and pharmaceutical composition for treating cancer | |
| CN113316459A (zh) | 包含皮肤穿透核酸复合物作为有效成分的用于预防或治疗特应性皮炎的组合物 | |
| EP3775211A1 (en) | Sirt1-sarna compositions and methods of use | |
| WO2020208361A1 (en) | Sirt1-sarna compositions and methods of use | |
| AU2018101287A4 (en) | Method and pharmaceutical composition for treating cancer | |
| CA2980975C (en) | C/ebp alpha sarna compositions and methods of use | |
| Levi | Molecular medicine: Promises and patience | |
| CN104174031A (zh) | 逆转肿瘤多药耐药的基因组合物-h-R3/PAMAM G5/GCS siRNA及其应用 | |
| Gayral et al. | Modulating MicroRNA Expression for the Therapy of Pancreatic Cancer |